Current Rating and Its Significance
The Strong Sell rating assigned to Vivo Bio Tech Ltd. indicates a cautious stance for investors, suggesting that the stock is expected to underperform relative to the broader market and its peers in the Pharmaceuticals & Biotechnology sector. This rating is derived from a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the company’s investment appeal and risk profile.
Quality Assessment: Below Average Fundamentals
As of 02 April 2026, Vivo Bio Tech Ltd. exhibits below average quality metrics. The company’s long-term fundamental strength is weak, with a compounded annual growth rate (CAGR) of operating profits at a modest 2.30% over the past five years. This slow growth rate signals limited expansion and operational efficiency challenges. Furthermore, the company’s ability to service its debt is constrained, reflected in a poor EBIT to Interest ratio averaging 1.74, indicating that earnings before interest and taxes are only marginally sufficient to cover interest expenses.
Profitability metrics also highlight concerns. The average Return on Equity (ROE) stands at 6.60%, which is low for the sector, suggesting that the company generates limited profit relative to shareholders’ equity. Additionally, the latest half-year results show a significant decline in profitability, with the Profit After Tax (PAT) at ₹2.12 crores shrinking by 64.96%. The Return on Capital Employed (ROCE) for the half-year is also subdued at 7.95%, underscoring inefficiencies in capital utilisation.
Valuation: Very Attractive but Reflective of Risks
Despite the weak fundamentals, Vivo Bio Tech Ltd. is currently valued very attractively. This valuation grade suggests that the stock price is low relative to its earnings, book value, or cash flows, potentially offering a bargain for value-oriented investors. However, the attractive valuation must be interpreted cautiously, as it often reflects underlying risks and market scepticism about the company’s future prospects. The microcap status of the company further adds to the volatility and liquidity concerns, which investors should factor into their decision-making process.
Financial Trend: Flat Performance Amidst Challenges
The financial trend for Vivo Bio Tech Ltd. is flat, indicating stagnation rather than growth. The company’s recent financial results have not shown meaningful improvement, with key ratios such as the Debtors Turnover Ratio at a low 3.54 times, signalling potential inefficiencies in receivables management. The flat trend is also evident in the stock’s returns, which have been negative across multiple time frames. As of 02 April 2026, the stock has delivered a -35.92% return over the past year and a -27.68% return over the last three months, underperforming the BSE500 benchmark consistently over one, three, and six-month periods.
Technical Outlook: Bearish Momentum
Technically, Vivo Bio Tech Ltd. is in a bearish phase. The stock’s price action and momentum indicators suggest downward pressure, with recent declines of 12.45% over one month and 8.49% over one week. The bearish technical grade reinforces the cautionary stance implied by the fundamental and financial assessments, signalling that the stock may continue to face selling pressure in the near term.
Stock Returns and Market Performance
Examining the stock’s returns as of 02 April 2026 provides further context for the Strong Sell rating. The stock’s one-day change is marginally positive at +0.04%, but this is overshadowed by significant declines over longer periods: -8.49% over one week, -12.45% over one month, -27.68% over three months, and -37.85% over six months. Year-to-date, the stock has lost 26.97%, and over the past year, it has declined by 35.92%. These figures highlight sustained underperformance relative to broader market indices and sector peers.
Implications for Investors
For investors, the Strong Sell rating on Vivo Bio Tech Ltd. serves as a signal to exercise caution. The combination of weak quality metrics, flat financial trends, bearish technical signals, and although attractive valuation, a microcap status with significant downside risk, suggests that the stock may not be suitable for risk-averse portfolios. Investors should carefully consider these factors alongside their investment horizon and risk tolerance before taking a position in the stock.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Company Profile and Market Context
Vivo Bio Tech Ltd. operates within the Pharmaceuticals & Biotechnology sector, a space characterised by high research and development costs, regulatory challenges, and competitive pressures. The company’s microcap market capitalisation reflects its relatively small size and limited market presence. In such a sector, companies with strong innovation pipelines, robust financial health, and positive technical momentum tend to attract investor interest. Vivo Bio Tech Ltd.’s current metrics, however, indicate it is struggling to meet these benchmarks.
Summary of Key Metrics as of 02 April 2026
The Mojo Score for Vivo Bio Tech Ltd. stands at 26.0, categorised as Strong Sell, down from a previous score of 31 (Sell) as of 19 January 2026. The quality grade remains below average, valuation is very attractive, financial trend is flat, and technical grade is bearish. The company’s operating profit growth CAGR is a modest 2.30%, EBIT to Interest ratio averages 1.74, and ROE is 6.60%. Recent half-year results show a PAT decline of 64.96% and a ROCE of 7.95%. The stock’s returns have been negative across all key time frames, reflecting ongoing challenges.
Conclusion: A Cautious Approach Recommended
In conclusion, Vivo Bio Tech Ltd.’s Strong Sell rating by MarketsMOJO is grounded in a thorough analysis of its current financial and market position as of 02 April 2026. While the valuation appears attractive, the company’s weak fundamentals, flat financial trends, and bearish technical outlook suggest significant risks remain. Investors should weigh these factors carefully and consider alternative opportunities with stronger growth prospects and financial health within the Pharmaceuticals & Biotechnology sector.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
